Company Announces Launch of New Website www.Polydex.com
September 08 2011 - 10:32AM
Polydex Pharmaceuticals Limited (Pink
Sheets:POLXF) (the "Company") is pleased to announce the launch of
a newly updated company website at www.Polydex.com.
The new, simpler website provides an introduction to the
Company, provides access to recent news releases and other company
information as it becomes available, and includes links to current
stock quotes and charts. Shareholders and visitors can also now
subscribe to receive News Releases directly from the Company
website.
The Company has also recently launched a new website at
www.Dextran.ca highlighting its core-product line, production
facilities, company history and management.
The Company shares continue to be quoted on the Pink Sheet
platform (www.pinksheets.com).
Polydex Pharmaceuticals Limited, based in Toronto, Ontario,
Canada, is engaged in the development, manufacture and marketing of
biotechnology-based products for the human pharmaceutical market,
and also manufactures bulk pharmaceutical intermediates for the
worldwide veterinary pharmaceutical industry.
The Polydex Pharmaceuticals Limited logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3414
Note: This press release may contain forward-looking
statements, within the meaning of the United States Securities Act
of 1933, as amended, and the United States Securities Exchange Act
of 1934, as amended, regarding Polydex Pharmaceuticals Limited,
including, without limitation, statements regarding expectations
about future revenues or business opportunities or potential
research projects. These statements are typically identified by use
of words like "may," "could," "might," "expect," "anticipate,"
"believe," or similar words. Actual events or results may differ
materially from the Company's expectations, which are subject to a
number of known and unknown risks and uncertainties including but
not limited to changing market conditions, future actions by the
United States Food and Drug Administration or equivalent foreign
regulatory authorities as results of pending or future clinical
trials. Other risk factors discussed in the Company's filings with
the United States Securities and Exchange Commission may also
affect the actual results achieved by the Company.
CONTACT: Investor Relations:
North Arm Capital Services
Linda Hughes
1-877-945-1621
(Linda@northarm.com)
Polydex Pharmaceuticals (PK) (USOTC:POLXF)
Historical Stock Chart
From Apr 2024 to May 2024
Polydex Pharmaceuticals (PK) (USOTC:POLXF)
Historical Stock Chart
From May 2023 to May 2024